By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > ARB > Telmisartan

Telmisartan

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|628 words

Telmisartan Drug Profile

What is Telmisartan?

Telmisartan is an angiotensin receptor blocker (ARB) used primarily to treat high blood pressure and reduce cardiovascular risk. It belongs to a class of medications that work by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict. Telmisartan is available as an oral tablet and is often prescribed as part of a comprehensive treatment plan for hypertension and heart protection.

Uses

Telmisartan has several approved medical uses:

  • Hypertension treatment: The primary use is lowering high blood pressure in adults, helping reduce the risk of stroke, heart attack, and kidney problems
  • Cardiovascular risk reduction: Prescribed for patients at high risk of cardiovascular events, including those with coronary artery disease or diabetes
  • Diabetic nephropathy prevention: Helps protect kidney function in people with type 2 diabetes who are at risk of kidney damage
  • Heart failure management: Sometimes used as part of treatment for certain types of heart failure when other medications are not suitable
  • Post-heart attack protection: May be prescribed to reduce the risk of future cardiovascular events in patients who have experienced a heart attack

How it works

Telmisartan works by blocking angiotensin II receptors in blood vessels, preventing this hormone from causing blood vessel constriction and sodium retention. When these receptors are blocked, blood vessels relax and widen, which lowers blood pressure and reduces the workload on the heart. This mechanism also helps protect the kidneys from damage caused by high blood pressure and diabetes.

Side effects

Common side effects:

Submit Your Paper
GMJ_Submit_Banner
  • Dizziness or lightheadedness
  • Upper respiratory tract infections
  • Back pain
  • Fatigue
  • Diarrhea
  • Sinus congestion
  • Headache
  • Muscle pain

Serious side effects requiring immediate medical attention:

  • Severe drop in blood pressure (hypotension)
  • Kidney function deterioration
  • High potassium levels (hyperkalemia)
  • Severe allergic reactions including swelling of face, lips, or throat
  • Liver problems with symptoms like yellowing of skin or eyes

Warnings and precautions

  • Pregnancy: Telmisartan is contraindicated during pregnancy, especially in the second and third trimesters, as it can cause fetal harm including kidney problems and death
  • Kidney impairment: Patients with severe kidney disease should use telmisartan with caution, and kidney function should be monitored regularly during treatment
  • Liver problems: Those with severe liver impairment may need dose adjustments or alternative treatments
  • Dehydration risk: Patients who are dehydrated, on dialysis, or taking diuretics have increased risk of low blood pressure
  • Surgery considerations: The medication may need to be temporarily discontinued before major surgery due to blood pressure effects during anesthesia

Interactions

Telmisartan can interact with several medications and supplements:

  • Potassium supplements and salt substitutes: Can increase potassium levels to dangerous levels
  • Lithium: Telmisartan may increase lithium levels, potentially causing toxicity
  • NSAIDs (ibuprofen, naproxen): May reduce the blood pressure-lowering effect and increase kidney damage risk
  • Diuretics: Can cause excessive blood pressure reduction, especially when starting treatment
  • ACE inhibitors: Combining with telmisartan increases risk of kidney problems and high potassium
  • Digoxin: May increase digoxin levels, requiring monitoring for toxicity
  • Warfarin: May affect blood clotting times, requiring more frequent monitoring
  • Diabetes medications: May enhance blood sugar-lowering effects

Check interactions with the GMJ Interaction Checker

Dosage

For adults with hypertension, the typical starting dose is 40 mg once daily, which may be increased to 80 mg daily if needed for blood pressure control. For cardiovascular risk reduction, the usual dose is 80 mg once daily. Patients with kidney or liver impairment may require lower doses. Telmisartan can be taken with or without food, and should be taken at the same time each day for best results. Dosage adjustments should always be made by a healthcare provider based on individual patient response and medical conditions.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Telmisartan." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/telmisartan-2/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
How Political Pressure on Science Agencies Threatens Public Health Decision-Making

Political interference in federal scientific agencies delays evidence-based decision-making and undermines public…

UK Health and Safety Authorities Issue Joint Warning on Asbestos in Consumer Products

UK regulatory authorities issue joint warning on asbestos contamination in imported consumer…

UK Releases Rabies Post-Exposure Risk Assessment Tool for Clinical Practice

The UK Department of Health and Social Care has published a standardised…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Olmesartan

By
Prof. Giorgi Pkhakadze
02/06/2026

Azilsartan

By
Prof. Giorgi Pkhakadze
02/06/2026

Losartan

By
Prof. Giorgi Pkhakadze
01/06/2026

Olmesartan

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up